BARINTHUS BIOTHERAPEUTICS PL (BRNS) Stock News

USA - NASDAQ:BRNS - US91864C1071 - ADR

1.0812 USD

-0.02 (-2.15%)

Last: 9/19/2025, 8:00:01 PM

1.09 USD

+0.01 (+0.81%)

After Hours: 9/19/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BRNS Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: EQ OMI BTAI HUMA ...

12 Health Care Stocks Moving In Monday's Intraday Session

a month ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

a month ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

2 months ago - By: Benzinga - Mentions: RFL CYCC CRL ONMD ...

12 Health Care Stocks Moving In Monday's After-Market Session

7 months ago - By: ACCESS Newswire

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

a year ago - By: BusinessInsider

News Image

BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024

3 months ago - By: ACCESS Newswire - Mentions: MNRG.CA OPHC XHLD ROLR ...

Q2 Virtual Investor Summit: Presentations Available Now

3 months ago - By: ACCESS Newswire

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

5 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

5 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

6 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

6 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

6 months ago - By: ACCESS Newswire - Mentions: DRTS GIFT VOXR FEMY ...

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

8 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

8 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

10 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

10 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

10 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

10 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

10 months ago - By: Barinthus Biotherapeutics - Mentions: ABUS

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

11 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

11 months ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

a year ago - By: InvestorPlace

BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results

a year ago - By: Sagimet Biosciences Inc. - Mentions: SGMT TRVN RCUS ZURA ...

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

a year ago - By: Barinthus Biotherapeutics

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections